Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience

Table 2 Disease Characteristics, Past Illnesses, and Surgical History

Category	CAPTURE (N = 150)
Mean (±SD) time from diagnosis to discharge, d	10.1 (±42.0)
Disease characteristics, n (%)
Associated with hardware	32 (21.3)
Associated complications^a
Any	132 (88.0)
ABSSSI	99 (66.0)
Secondary bacteremia	25 (16.7)
Other	18 (12.0)
Primary site of infection^a
Foot	84 (56.0)
Spine	24 (16.0)
Leg or thigh	18 (12.0)
Hip	13 (8.7)
Other	17 (11.3)
Laboratory results,^b
Mean (±SD) total white blood cell count, cells/mm³	9703.4 (±4228.5)
Mean (±SD) serum creatinine, mg/dL	1.6 (±2.0)
Mean (±SD) hemoglobin A1c^c	8.1 (±2.1)
Past illnesses,^a n (%)
DM	87 (58.0)
PAD	23 (15.3)
DM or PAD	89 (59.3)
DM and PAD	21 (14.0)
Current or recent IV drug use	2 (1.3)
Surgical history during CPT-F therapy,^a n (%)
Amputation	10 (6.7)
Incision and drainage	4 (2.7)
Debridement	3 (2.0)
Other	5 (3.3)

ABSSSI acute bacterial skin and skin structure infection, CPT-F ceftaroline fosamil, DM diabetes mellitus, IV intravenous, PAD peripheral arterial disease, SD standard deviation
^aCategories not mutually exclusive
^bBefore treatment with CPT-F
^cMeasurements taken 2 months before treatment through the end of treatment